Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
08/2003
08/21/2003WO2002064748A3 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
08/21/2003WO2002057452A3 Human proteins, polynucleotides encoding them and methods of using the same
08/21/2003WO2002046158A3 Piperidine/piperazine-type inhibitors of p38 kinase
08/21/2003WO2002036573A3 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
08/21/2003WO2002036162A3 Compositions for treatment of ocular neovascularization and neural injury
08/21/2003WO2002020722A9 Methods and compositions for in vitro targeting
08/21/2003WO2002013801A3 Method of treating the syndrome of coronary heart disease risk factors in humans
08/21/2003WO2002002512A3 Compounds to treat alzheimer's disease
08/21/2003US20030158424 Substituted alpha, beta-anellated butyrolactones
08/21/2003US20030158413 A thiochromane-7-carboxamide derivatives as Rho kinase enzyme inhibitor; nontoxic, anticancer agents
08/21/2003US20030158409 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
08/21/2003US20030158406 Enzyme inhibitor treating autoimmune diseases, Alzheimer's disease, atherosclerosis
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158266 Particularly septic shock
08/21/2003US20030158252 Especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa.
08/21/2003US20030158248 N-(2-(1-amidinopyrrol-3-yl)ethyl)-5,6-dihydroxy-1-(2-(2-methox y-3-sulfatopropionylamino)-3-chloro-4-methylvaleroyl)indole-2-carboxamide
08/21/2003US20030158244 Methods of treatment using a gastric retained losartan dosage
08/21/2003US20030158242 Salt with a sugar substitute, especially saccharin, cyclamate or acesulfame.
08/21/2003US20030158238 Treating diseases such as cancer, inflammatory disorders, restenosis,
08/21/2003US20030158234 Use for deferiprone
08/21/2003US20030158233 Compositions and methods for treating heart failure
08/21/2003US20030158225 Novel compounds
08/21/2003US20030158219 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
08/21/2003US20030158207 N-benzylpiperazine compounds
08/21/2003US20030158203 Triazolo-pyridazine derivatives as ligands for GABA receptors
08/21/2003US20030158201 Method for treating septic shock
08/21/2003US20030158200 E.g., 6-(4-(N'-(4-hydroxy-3-methoxy-2-nitrobenzylidene)-hydrazino)phenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one
08/21/2003US20030158197 Certain alkylene diamine-substituted heterocycles
08/21/2003US20030158194 Treating Congestive heart failure with a diethylamineethyloxy phenylketone benzofuran compounds
08/21/2003US20030158189 Non-steroidal antiinflammatory agents treating bone disorders, Crohn's disease, and inflammatory bowel disease, respiratory disorders such as chronic obstructive pulmonary disease, infections, autoimmune diseases
08/21/2003US20030158187 Genetic polymorphisms in the preprotachy kinin gene
08/21/2003US20030158183 Method of treating schizophrenia
08/21/2003US20030158181 Method for treating cerebral ishaemia
08/21/2003US20030158179 Quinoline derivatives
08/21/2003US20030158173 NK 1 antagonists
08/21/2003US20030158146 Chemical compounds
08/21/2003US20030158133 Use of such inhibitors or activators in treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments
08/21/2003US20030158122 For treatment of hyperlipidemia and blood coagulation disorders and to reduce levels of virus, bacteria, and endotoxins in blood stream
08/21/2003US20030158121 Novel $G(y)crystalline form of perindopril tert- butylamine salt, preparation method, and pharmaceutical compositions containing same
08/21/2003US20030158119 Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on
08/21/2003US20030158113 Administering to individual a therapeutically effective amount of osteopontin or a functional fragment
08/21/2003US20030158099 Cancer therapy
08/21/2003US20030158094 Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product
08/21/2003US20030158081 Genetic polymorphisms in the human HMG-CoA reductase gene and their use in diagnosis and treatment of diseases
08/21/2003US20030157704 Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
08/21/2003US20030157599 Comprises nucleotide sequence coding prostaglandin E receptor (EP3) for diagnosis and treatment of atherosclerotic diseases; restriction fragment length polymorphisms
08/21/2003US20030157552 Providing a screening assay having stearoyl-CoA desaturase biological activity, contacting sceening assay with a test compound and measuring the biological activity
08/21/2003US20030157531 TAOJIKs as modifiers of the beta-catenin pathway and methods of use
08/21/2003US20030157516 Medical diagnosis; binding with adenine
08/21/2003US20030157225 Food product and process
08/21/2003US20030157173 Timed, sustained release systems for propranolol
08/21/2003US20030157171 Chitosan-xanthane hydrogel including in its matrix a poorly water soluble drug which upon swelling of hydrogel in aqueous medium becomes at least partially solubilized and releasable therefrom
08/21/2003US20030157144 Desaturase genes and uses thereof
08/21/2003US20030157138 Pharmaceutical or cosmetic carrier or composition for topical application onto skin and/or mucosal membranes; treatment of skin diseases or disorders including eczema, psoriasis and dermatitis
08/21/2003US20030157108 80-100% of the glycoprotein has a mature core carbohydrate structure which lacks fucose, attached to a Fc region
08/21/2003US20030157099 Human trk receptors and neurotrophic factor inhibitors
08/21/2003US20030157084 Methods for preparing purified prostaglandin E synthase
08/21/2003US20030157064 Actin gene promoter; genetic engineered polypeptide; cardiovascular disorders
08/21/2003US20030157030 Methods and compositions for therapeutic use of rna interference
08/21/2003DE19937304C2 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen Use of CGRP antagonists for the control of menopausal hot flushes
08/21/2003CA2476553A1 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
08/21/2003CA2476454A1 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003CA2476446A1 Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases
08/21/2003CA2476239A1 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003CA2476162A1 Jnk inhibitor
08/21/2003CA2476113A1 Beta-sheet mimetics and composition and methods relating thereto
08/21/2003CA2476027A1 Alpha-substituted arylalkyl phosphonate derivatives
08/21/2003CA2475882A1 Alpha-substituted heteroarylalkyl phosphonate derivatives
08/21/2003CA2475838A1 Cytotoxic t-cell epitopes from chlamydia
08/21/2003CA2475708A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003CA2475703A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003CA2475659A1 Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation
08/21/2003CA2475522A1 Method of radio-labelling biomolecules
08/21/2003CA2475439A1 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
08/21/2003CA2475338A1 Treatment of ophthalmic disorders using urea and urea derivatives
08/21/2003CA2474670A1 Diagnostic method for stroke
08/21/2003CA2472822A1 Chemical compounds
08/21/2003CA2472762A1 2-oxazolamines and their use as 5-ht2b receptor antagonists
08/21/2003CA2372785A1 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
08/20/2003EP1336605A1 Substituted benzene derivatives or salts thereof
08/20/2003EP1336600A2 Dimer-selective RXR modulators and methods for their use
08/20/2003EP1336413A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
08/20/2003EP1336407A1 Medicinal compositions
08/20/2003EP1335939A1 Nitroderivatives of polysaccharides
08/20/2003EP1335938A2 Apolipoprotein analogues
08/20/2003EP1335937A2 Mixed fibrils
08/20/2003EP1335924A2 Ethers of 7-desmethylrapamycin for use in immunosuppression
08/20/2003EP1335923A2 Condensed pyridoindole derivatives
08/20/2003EP1335919A1 Novel compounds
08/20/2003EP1335918A1 Novel compounds
08/20/2003EP1335917A2 Condensed pyridoindole derivatives
08/20/2003EP1335916A1 Pyridyl-substituted triazoles as tgf inhibitors
08/20/2003EP1335912A1 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors
08/20/2003EP1335908A2 Peroxisome proliferator activated receptor alpha agonists
08/20/2003EP1335902A1 Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them
08/20/2003EP1335901A1 Pharmaceutically active sulfanilide derivatives
08/20/2003EP1335759A1 Porous polymeric biomaterials, preparation method and uses
08/20/2003EP1335746A2 Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis
08/20/2003EP1335736A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders
08/20/2003EP1335707A2 Novel formulations of carvedilol
1 ... 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 ... 1595